Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B666 Allele Carriers.

Journal of cardiovascular electrophysiology - 1 Oct 2016

Abdelhady Ahmed M, Shugg Tyler, Thong Nancy, Lu Jessica Bo Li, Kreutz Yvonne, Jaynes Heather A, Robarge Jason D, Tisdale James E, Desta Zeruesenay, Overholser Brian R

Abstract excerpt

BACKGROUND: Efavirenz (EFV) has been associated with torsade de pointes despite marginal QT interval lengthening. Since EFV is metabolized by the cytochrome P450 (CYP) 2B6 enzyme, we hypothesized that EFV would lengthen the rate-corrected QT (QTcF) interval in carriers of the CYP2B6*6 decreased functional allele. OBJECTIVE: The primary objective of this study was to evaluate EFV-associated QT interval changes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Benzoxazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to Cytochrome P-450 CYP2B6

Share to ERG1 Potassium Channel

Share to Healthy Volunteers

Share to Potassium Channel Blockers

Share to Torsades de Pointes

Source

Open in PubMed Open full text

Identifiers

PMID: 27333947
DOI: 10.1111/jce.13032
PMCID: PMC5065384

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers.PMID 27333947Read ↗

Population pharmacogenetic‐based pharmacokinetic modeling of efavirenz, 7‐hydroxy‐ and 8‐hydroxyefavirenzSemantic proximity Read ↗

Acquired QT interval prolongation and HERG: implications for drug discovery and development.Semantic proximity Read ↗

Block of the human ether-a-go-go-related gene (hERG) K+ channel by the antidepressant desipramine.Semantic proximity Read ↗

Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patientsSemantic proximity Read ↗

H(1) antihistamine drug promethazine directly blocks hERG K(+) channel.Semantic proximity Read ↗

Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz.Semantic proximity Read ↗

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.Semantic proximity Read ↗

Efavirenz in the therapy of HIV infectionSemantic proximity Read ↗

Impact of pharmacogenetics on CNS side effects related to efavirenz.Semantic proximity Read ↗

High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe.Semantic proximity Read ↗

Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.Semantic proximity Read ↗

Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.